Goodwin-Led Cabaletta Prices Below Range With $75M IPO
Autoimmune disease-focused Cabaletta Bio Inc. on Friday priced a $75 million initial public offering steered by Goodwin Procter LLP that fell well below the clinical stage company's targeted range....To view the full article, register now.
Already a subscriber? Click here to view full article